Confident decision-making
Who will benefit from anti-PD-1/PD-L1 monotherapy?
Strata Select provides you with the information you need to make a critical treatment decision for your patients with advanced cancer – whether to prescribe single agent immunotherapy or combination therapy.
With Strata Select you can:
- Find new patient populations likely to respond
- Avoid unnecessary combination chemotherapy
Immunotherapy
Response Score
Immunotherapy Response Score is a pan-solid tumor predictive
diagnostic tool for anti-PD-1/PD-L1 monotherapy benefit.
This innovative biomarker algorithm captures the biology of the
tumor and its microenvironment by combining tumor mutation
burden (TMB) with quantitative expression of PD-L1, PD-1,
ADAM12 and TOP2A.
Genomic Signatures
Strata Select also provides the following genomic signatures:
- Tumor mutation burden (TMB)
- Microsatellite instability (MSI)
Genomic Signatures
Strata Select also provides the following genomic signatures:
- Tumor mutation burden (TMB)
- Microsatellite instability (MSI)
Comprehensive
Genomic Profiling
Strata Select analyzes DNA and RNA across 437
genes to provide guidance for genomic-alteration
targeted therapies.
DNA analysis
All classes of genomic variants are analyzed:
- Single-/multi-nucleotide variants (SNVs)
- Short insertions and deletions (indels)
- Copy number alterations (CNAs)
- Amplifications and deep deletions
RNA analysis
Targeted RNA sequencing enables analysis of 950
individual fusion isoforms involving 59 primary
driver genes.
DNA analysis
All classes of genomic variants are analyzed:
- Single-/multi-nucleotide variants (SNVs)
- Short insertions and deletions (indels)
- Copy number alterations (CNAs)
- Amplifications and deep deletions
RNA analysis
Targeted RNA sequencing enables analysis of 950
individual fusion isoforms involving 59 primary
driver genes.
Comprehensive
Genomic Profiling
Strata Select analyzes DNA and RNA across 437
genes to provide guidance for genomic-alteration
targeted therapies.
Supplemental Insights
Supplemental results based on quantitative RNA sequencing
can be used to help expand treatment selection beyond
immunotherapy and mutation-guided therapies to expression-
based therapeutic classes such as antibody-drug conjugates.
Results may be useful for correlating with treatment response to
approved or investigational therapies, or may confer eligibility for
clinical trials.
Homologous recombination deficiency (HRD) results are
provided for patients with ovarian cancer.
Easy-to-read reports
All the information you
need at a glance
This concise, consolidated view of each patient’s results includes:
- Molecular diagnosis
- Pertinent biomarkers
- Therapy associations
- Therapy rationale